Daiwa Securities Group’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,449
| Closed | -$76K | – | 1244 |
|
|
2025
Q4 | $76K | Sell |
1,449
-196
| -12% | -$11.7K | ﹤0.01% | 1063 |
|
|
2025
Q3 | $107K | Sell |
1,645
-155
| -9% | -$8.9K | ﹤0.01% | 1036 |
|
|
2025
Q2 | $88K | Buy |
1,800
+1,518
| +538% | +$58.7K | ﹤0.01% | 1005 |
|
|
2025
Q1 | $10K | Hold |
282
| – | – | ﹤0.01% | 1095 |
|
|
2024
Q4 | $11K | Sell |
282
-45
| -14% | -$2.13K | ﹤0.01% | 1111 |
|
|
2024
Q3 | $15K | Buy |
327
+30
| +10% | +$1.52K | ﹤0.01% | 1113 |
|
|
2024
Q2 | $16K | Sell |
297
-1,080
| -78% | -$62.5K | ﹤0.01% | 1139 |
|
|
2024
Q1 | $94K | Sell |
1,377
-88
| -6% | -$6.3K | ﹤0.01% | 1049 |
|
|
2023
Q4 | $92K | Sell |
1,465
-198
| -12% | -$10.9K | ﹤0.01% | 1026 |
|
|
2023
Q3 | $75K | Hold |
1,663
| – | – | ﹤0.01% | 1035 |
|
|
2023
Q2 | $93K | Buy |
1,663
+1,348
| +428% | +$76.5K | ﹤0.01% | 1019 |
|
|
2023
Q1 | $14K | Hold |
315
| – | – | ﹤0.01% | 1087 |
|
|
2022
Q4 | $13K | Buy |
315
+26
| +9% | +$1.38K | ﹤0.01% | 1099 |
|
|
2022
Q3 | $19K | Hold |
289
| – | – | ﹤0.01% | 1100 |
|
|
2022
Q2 | $18K | Sell |
289
-1,624
| -85% | -$95.5K | ﹤0.01% | 1120 |
|
|
2022
Q1 | $120K | Buy |
1,913
+530
| +38% | +$33.3K | ﹤0.01% | 1020 |
|
|
2021
Q4 | $105K | Buy |
1,383
+548
| +66% | +$47.9K | ﹤0.01% | 1004 |
|
|
2021
Q3 | $93K | Buy |
835
+686
| +460% | +$86.2K | ﹤0.01% | 998 |
|
|
2021
Q2 | $24K | Hold |
149
| – | – | ﹤0.01% | 1012 |
|
|
2021
Q1 | $18K | Buy |
149
+16
| +12% | +$2.42K | ﹤0.01% | 1016 |
|
|
2020
Q4 | $20K | Sell |
133
-255
| -66% | -$30.1K | ﹤0.01% | 984 |
|
|
2020
Q3 | $32K | Buy |
388
+52
| +15% | +$4.61K | ﹤0.01% | 961 |
|
|
2020
Q2 | $32K | Hold |
336
| – | – | ﹤0.01% | 946 |
|
|
2020
Q1 | $14K | Hold |
336
| – | – | ﹤0.01% | 1032 |
|
|
2019
Q4 | $19K | Sell |
336
-12
| -3% | -$655 | ﹤0.01% | 1017 |
|
|
2019
Q3 | $14K | Buy |
348
+16
| +5% | +$765 | ﹤0.01% | 1012 |
|
|
2019
Q2 | $16K | Hold |
332
| – | – | ﹤0.01% | 1026 |
|
|
2019
Q1 | $12K | Buy |
332
+78
| +31% | +$2.7K | ﹤0.01% | 1023 |
|
|
2018
Q4 | $7K | Hold |
254
| – | – | ﹤0.01% | 1024 |
|
|
2018
Q3 | $11K | Hold |
254
| – | – | ﹤0.01% | 1029 |
|
|
2018
Q2 | $15K | Hold |
254
| – | – | ﹤0.01% | 1023 |
|
|
2018
Q1 | $12K | Buy |
+254
| New | +$10.5K | ﹤0.01% | 1017 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
Daiwa Securities Group's CRSP Position: Q1 2026 in Review
Daiwa Securities Group sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 1,449 shares — an estimated $76K sold.
Daiwa Securities Group first reported a position in CRSP in Q1 2018 and held it in 32 quarters. The position peaked at $120K in Q1 2022. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.
- Daiwa Securities Group reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
- Daiwa Securities Group sold 1,449 CRISPR Therapeutics shares in Q1 2026, an estimated $76K.
- Daiwa Securities Group first reported a position in CRISPR Therapeutics in Q1 2018 and held it in 32 quarters.
- Daiwa Securities Group's CRISPR Therapeutics position peaked at $120K in Q1 2022.
- 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.
Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.